

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Martin S. Linsell

Examiner: Unknown

09/847,060

Group Art Unit: Unknown

Filed:

May 1, 2001

Docket: 1343.004US1

Title:

REDUCTIVE ALKYLATION PROCESS

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seg., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicant further request that a copy of the 1449 form, initialled by the Examiner to indicate that all listed citations have been considered, be returned with the next official communication.

Under 37 C.F.R. §1.97(b)(3), it is believed that no fee or certificate is required with this Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge any additional fees or credit any overpayment to Account No. 19-0743.

The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

MARTIN S. LINSELL

By his Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938

Minneapolis, MN 55402

(612) 359-3265

Name


Robert J. Harris, Ph.D.

Reg. No. 37,346

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this

Alisia G. Dunbar

Signature



Atty. Docket No.: 1343.004US1

Filing Date: May 1, 2001

Serial No. 09/847,060

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT
Applicant: Martin S. Linsell

Group: Unknown

(Oct.

(Use several sheets if necessary)

xaminer nitial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
,		00/15/1005	Managadan ah al	C14	0	08/14/85
	_ 4,643,987	02/17/1987	Nagarajan et al.	514 514	8 8	04/18/86
	_ 4,698,327	10/06/1987	Nagarajan et al.	51 4 514	9	10/13/94
	_ 5,591,714	01/07/1997	Nagarajan et al.	514	11	04/30/96
	_ 5,750,509	05/12/1998	Malabarba et al.	514 514	11	03/24/95
	_ 5,840,684	11/24/1998	Cooper et al.	_	9	04/01/98
	_ 5,916,873	06/29/1999	Cooper et al.	514		11/12/97
	_ 5,952,466	09/14/1999	Berglund et al.	530	345	
	_ 5,998,581	12/07/1999	Berglund et al.	530	345	04/12/99
		FC	REIGN PATENT DOCUMENT	rs		
aminer itial	Document Number	Date	Country	Class	Subclass	Translation Yes No
	_ 00/39156	07/06/2000	PCT	C07K	9/00	
	_ 00/59528	10/12/2000	PCT	A61K	38/08	
	_ 0667353	08/16/1995	European	C07K	9/00	
	_ 0816378	01/07/1998	European	C07K	9/00	
	_ 98/21952	05/28/1998	PCT	A01N	37/18	
	_ 99/42476	08/26/1999	PCT	C07K	7/50	
			OMITTED DOCUMENTED			
aminer		(Including	OTHER DOCUMENTS Author, Title, Date, Pertinent Pag	ges, Etc.)		
itial						
	Cooper, R.	D., et al., "	Reductive Alkylation	of Glycop	eptide Ar	tibiotics:
	Synthesis	and Antibacter	ial Activity", The Jo	ournal of	<u>Antibioti</u>	<u>.cs, 49 (6)</u> ,
	pp. 575-58	1, (June 1996)	·		
	Nagarajan,	R., et al.,	"Synthesis and Antiba	acterial E	valuation	of N-Alkyl
	Vancomycin	s", <u>The Journa</u>	l of Antibiotics, XLI	<u>[I (1)</u> , p	p. 63-72	2, (Jan. 1989
	Nicolaou,	K.C., et al.,	"Chemistry, Biology,	, and Medi	cine of t	
	Antibiotic	s", <u>Angew. Che</u>	m. Int. Ed., 38, pp.	. 2097-215	2, (1999	9)
	Pavlov, A.	Y., et al., "	Chemical Modification	of Glyco	peptide A	ntibiotics
	[VC1] ", <u>Ru</u>	ssian Journal_	Of Bioorganic Chemist	ry, 24 (9	<u>)</u> , pp. 5	370-587, (199
	Rodriguez,	M.J., et al.,	"Novel Glycopeptide	Antibiot	ics: N-Al	kylated
		s Active Again	st Vancomycin-Resista	ant Enterc	cocci", <u>]</u>	he Journal of
	Antibiotic		. 560-569, (June 199			
			Enzymatic Deacylation			
			ynthesis and Antibact			

Examiner	Date Considered

Glycopeptides", The Journal of Antibiotics, 51 (10), pp. 945-951,

1998)

^{*}Substitute Disclosure Statement Form (PTO-1449)

^{**}EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.